Impact of Early Rejection Treatment on Infection Development in Kidney Transplant Recipients: A Propensity Analysis

Table 1

Demographics and clinical characteristics for control and case cohorts.

	Case (n = 185)	Control (n = 185)	value
Age at transplant			0.657^1
Mean (SD)	53.6 (14.0)	53.0 (14.6)
Male			0.675^2
No	82 (44.3%)	78 (42.2%)
Yes	103 (55.7%)	107 (57.8%)
Diabetes			0.596^2
No	108 (58.4%)	113 (61.1%)
Yes	77 (41.6%)	72 (38.9%)
BMI			0.428^1
Mean (SD)	28.6 (5.9)	28.1 (5.5)
Txp year			0.878^2
2014	31 (16.8%)	33 (17.8%)
2015	24 (13.0%)	26 (14.1%)
2016	23 (12.4%)	18 (9.7%)
2017	26 (14.1%)	21 (11.4%)
2018	35 (18.9%)	33 (17.8%)
2019	35 (18.9%)	44 (23.8%)
2020	11 (5.9%)	10 (5.4%)
Deceased donor			0.202^2
No	34 (18.4%)	44 (23.8%)
Yes	151 (81.6%)	141 (76.2%)
Induction therapy			0.948^2
Basiliximab	67 (36.2%)	69 (37.3%)
Alemtuzumab	104 (56.2%)	101 (54.6%)
Antithymocyte globulin	14 (7.6%)	15 (8.1%)
Steroid avoidance			0.746^2
No	119 (64.3%)	116 (62.7%)
Yes	66 (35.7%)	69 (37.3%)
eGFR at 4 months			0.935^1
Mean (SD)	49.7 (20.1)	49.5 (19.3)

The baseline demographics and clinical characteristics for both cohorts, after matching. There were no significant differences between the cohorts. Analysis completed using ¹two-sample t-test and ²Pearson’s chi-squared test.